Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05838456
Other study ID # HSC-MS-19-0630
Secondary ID UL1TR003167
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2021
Est. completion date May 27, 2022

Study information

Verified date June 2023
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

After onset of Acute Ischemic Stroke (AIS), every minute of delay to treatment reduces the likelihood of a good clinical outcome. A key delay occurs in the time between completion of computed tomography (CT) angiography of the head and neck and interpretation in the setting of AIS care. The purpose of this study is to assess the effect of incorporating Viz.AI software, which via via a machine-learning algorithm performs artificial intelligence-based automated detection of large vessel occlusions (LVO) on CT angiography (CTA) images and alerts the AIS care team (diagnosis and treatment decisions will be based on the clinical evaluation and review of the images by the treating physician, per routine standard of care). The hypothesis is that integration of the software into the AIS care pathway will reduce delays in treatment. A cluster-randomized stepped-wedge trial will be performed across 4 hospitals in the greater Houston area.


Recruitment information / eligibility

Status Completed
Enrollment 443
Est. completion date May 27, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or Female - 18 years of age or older. - Patients who present to the emergency department with signs and/or symptoms concerning for acute ischemic stroke. - Patients who undergo CT angiography imaging - Patients determined to have a large vessel occlusion acute ischemic stroke. This determination will be made based on official radiology report for the CT angiography imaging. Exclusion Criteria: - Patients with incomplete data on the electronic medical record.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Viz.AI software
Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.

Locations

Country Name City State
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston National Center for Advancing Translational Sciences (NCATS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) from the time of emergency room arrival to the time of initiation of endovascular stroke therapy (about 97 minutes)
Secondary Number of Patients Who Received With Endovascular Stroke Therapy at the time of initiation of endovascular stroke therapy
Secondary Number of Patients With Good Functional Outcome Defined as Modified Rankin Score (mRS) of 0-2 The modified Rankin Scale (mRS) is used to assess the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scales ranges from 0-6, as follows: 0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead. 90 days
Secondary Hospital Length of Stay The number of days of inpatient hospitalization. From the time of admission to the hospital to the time of discharge (about 7 days)
Secondary Number of Patients With Intracranial Hemorrhage (ICH) Number of participants with any intracranial hemorrhage (ICH) and symptomatic ICH (Defined by ECASS II criteria) From the time of admission to the hospital to the time of discharge (about 7 days)
See also
  Status Clinical Trial Phase
Recruiting NCT05585606 - Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke Phase 2
Completed NCT00821821 - Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke Phase 2